Stock Evaluator: Septerna, Inc. (SEPN)

Septerna, Inc. SEPN

$34.45 -0.73 -2.08%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 241,093
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Commentary & Analysis


Financial Summary

Share Statistics SEPN Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,585.3 $569.9 51%
Shares Out (Mil) 44.8 44.8 45%
Institutional Ownership 95.1% 84.6% 67%
Float (Mil) 23.2 45.1 31%
Beta na 0.67 na
Avg Daily Volume (000s) 235 294 47%
Price Change
(52-week)
175.8% 65.2% 97%
Growth SEPN Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.7% na
Net Income (5yr) na (2.0%) na
EPS (5yr) na 14.9% na
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) na (14.9%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 5 5 5
Current EPS ($0.493) ($1.839) ($2.659)
Month Ago EPS ($0.493) ($1.839) ($2.659)
# Rev Up 1 2 2
# Rev Down 0 2 0
Three Months Ago EPS ($0.173) ($1.191) ($1.945)
Year/Year Chg 155.4% 66.6% 141.8%
Financials SEPN Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $72 $230 23%
Net Income (TTM) (Mil) ($36) ($11) 19%
EPS (TTM) ($0.811) ($0.600) 23%
Operating Cash Flow (TTM) (Mil) $108 ($6) 53%
Net Cash Flow (TTM) (Mil) ($138) $4 12%
Long-Term Debt (Q1) (Mil) $21 $7 33%
Enterprise Value (Q1) (Mil) $696 $493 38%
Valuation SEPN Industry
Median
Percentile
(All Stocks)
P/B 4.17 2.89 74%
P/E na 20.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.1 na
Ratios SEPN Industry
Median
Percentile
(All Stocks)
Gross Margin 100.0% 65.9% 96%
Net Margin (49.9%) (0.2%) 11%
ROA (7.2%) (25.5%) 28%
ROE (9.3%) (21.4%) 28%
Liabilities to Assets 33.6% 35.5% 24%
F-Score 2 3 7%

Septerna, Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors